


CLAIMS

What is claimed is:

1. A compound, being a compound represented by Formula I-1 or Formula I-2; or being a tautomer, a stereoisomer, a hydrate, a solvate, or a salt, ~~or a prodrug~~ of the compound represented by Formula I-1 or Formula I-2,



wherein,

R^1 and R^2 are each independently selected from ~~H or CH_3~~ ,

provided that:


~~when R^1 and R^2 are not H simultaneously; or~~

~~when R^1 and R^2 are not CH_3 simultaneously.~~

2. The compound according to claim 1, wherein R^1 is ~~H~~, and R^2 is ~~CH_3~~ .

3. The compound according to claim 1, wherein R^1 is ~~CH_3~~ , and R^2 is ~~H~~.

4. The compound according to claim 1, wherein the compound is one of the following compounds; or a tautomer, a stereoisomer, a hydrate, a solvate, or a salt, ~~or a prodrug~~ of one of following compounds,



53. A pharmaceutical composition, comprising the compound according to ~~any one of~~
~~claims 1 to 4~~claim 1 or 2 as an active ingredient.

64. Use of the compound according to ~~any one of claims 1 to 4~~claim 1 or 2 or the
pharmaceutical composition according to claim 35 in manufacture of a medicament for treating
or preventing ATX-related diseases.

7. ~~The use according to claim 6, wherein the ATX-related diseases comprise~~ is selected
~~from the group consisting of at least one selected from~~ cancer, metabolic disease, kidney disease,
liver disease, fibrosis disease, interstitial lung disease, proliferation disease, inflammatory
disease, pain, autoimmune disease, respiratory disease, cardiovascular disease,
neurodegenerative diseases, dermatological disorder, ~~and/or~~ abnormal angiogenesis-related
disease, and combinations thereof.

85. The use according to claim 64, wherein the ATX-related diseases is selected from the
group consisting of ~~comprise at least one selected from~~ interstitial lung disease, pulmonary
fibrosis, liver fibrosis, ~~or~~ renal fibrosis, and a combination thereof.

96. The use according to claim 46, wherein the ATX-related disease iss ~~comprise~~ idiopathic
pulmonary fibrosis.

107. The use according to claim 46, wherein the ATX-related diseases ~~comprise~~ is selected

from the group consisting of type II diabetes, and nonalcoholic steatohepatitis, and a combination thereof.

118. The use according to claim 46, wherein the ATX-related diseases is selected from the group consisting of ~~comprise~~ neuropathic pain, ~~and~~ inflammatory pain, and a combination thereof.

129. The use according to claim 46, wherein the ATX-related diseases ~~comprise~~ is osteoarthritis-related pain.

1310. A drug combination, comprising:

the compound according to ~~any one of claims 1 to 4~~ claim 1 or 2 or the pharmaceutical composition according to claim 53; and

an additional drug for treating or preventing ATX-related diseases, wherein the ATX-related disease is selected from the group consisting of cancer, metabolic disease, kidney disease, liver disease, fibrosis disease, interstitial lung disease, proliferation disease, inflammatory disease, pain, autoimmune disease, respiratory disease, cardiovascular disease, neurodegenerative diseases, dermatological disorder, abnormal angiogenesis-related disease, and combinations thereof.

1411. The compound according to ~~any one of claims 1 to 4~~ claim 1 or 2, the pharmaceutical composition according to claim 35, or the drug combination according to claim 13-10 for use in ~~therapy of~~ treating or preventing ATX-related diseases, wherein the compound, the pharmaceutical composition, or the drug combination is to be administered to a patient:

15. ~~The compound, the pharmaceutical composition, or the drug combination for use according to claim 14, and~~ wherein the ATX-related diseases is selected from the group consisting of ~~comprise at least one selected from~~ cancer, metabolic disease, kidney disease, liver disease, fibrosis disease, interstitial lung disease, proliferation disease, inflammatory disease, pain, autoimmune disease, respiratory disease, cardiovascular disease, neurodegenerative diseases, dermatological disorder, ~~and/or~~ abnormal angiogenesis-related disease, and combinations thereof.